These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

439 related items for PubMed ID: 22234149

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events.
    Rosenstock J, Marx N, Neubacher D, Seck T, Patel S, Woerle HJ, Johansen OE.
    Cardiovasc Diabetol; 2015 May 21; 14():57. PubMed ID: 25990013
    [Abstract] [Full Text] [Related]

  • 3. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk.
    Rosenstock J, Perkovic V, Alexander JH, Cooper ME, Marx N, Pencina MJ, Toto RD, Wanner C, Zinman B, Baanstra D, Pfarr E, Mattheus M, Broedl UC, Woerle HJ, George JT, von Eynatten M, McGuire DK, CARMELINA® investigators.
    Cardiovasc Diabetol; 2018 Mar 14; 17(1):39. PubMed ID: 29540217
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.
    McGuire DK, Alexander JH, Johansen OE, Perkovic V, Rosenstock J, Cooper ME, Wanner C, Kahn SE, Toto RD, Zinman B, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, Marx N, CARMELINA Investigators.
    Circulation; 2019 Jan 15; 139(3):351-361. PubMed ID: 30586723
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years.
    Schernthaner G, Barnett AH, Patel S, Hehnke U, von Eynatten M, Woerle HJ.
    Diabetes Obes Metab; 2014 Nov 15; 16(11):1078-86. PubMed ID: 24865132
    [Abstract] [Full Text] [Related]

  • 11. Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression.
    Maiorino MI, Longo M, Scappaticcio L, Bellastella G, Chiodini P, Esposito K, Giugliano D.
    Cardiovasc Diabetol; 2021 Oct 18; 20(1):210. PubMed ID: 34663316
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (>10 years): evidence from pooled data of randomized, double-blind, placebo-controlled, phase III trials.
    Lajara R, Aguilar R, Hehnke U, Woerle HJ, von Eynatten M.
    Clin Ther; 2014 Nov 01; 36(11):1595-605. PubMed ID: 25236917
    [Abstract] [Full Text] [Related]

  • 18. Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients.
    McInnes G, Evans M, Del Prato S, Stumvoll M, Schweizer A, Lukashevich V, Shao Q, Kothny W.
    Diabetes Obes Metab; 2015 Nov 01; 17(11):1085-92. PubMed ID: 26250051
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of linagliptin according to patient baseline characteristics: A pooled analysis of three phase 3 trials.
    Del Prato S, Patel S, Crowe S, von Eynatten M.
    Nutr Metab Cardiovasc Dis; 2016 Oct 01; 26(10):886-92. PubMed ID: 27484756
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.